top of page
YT Channel banner.jpg

Why Are Healthcare Stocks Leading the ASX? How Pathology Data Connects the Top Movers to AI

Writer: Christopher Hall
Christopher Hall
6 hours ago
13 min read

Written by Christopher Hall, AdvDipFP | Authorised Representative, AFSL 526688 | Updated November 2026

ASX healthcare stocks are leading the market because artificial intelligence in medicine is limited by data rather than computing power, and pathology and diagnostics companies are the businesses that collect it. As at 9 November 2026, nine ASX-listed healthcare companies were recurring names in FMP's momentum data, with quarterly gains between 5.73% and 114.72%. Christopher Hall's research traced those nine to a global group of diagnostics leaders, where a single AI company connected the rest. This article sets out which companies are involved, how the group was identified, and what AI researcher Richard Socher says about why data is the bottleneck.

Christopher Hall walks through the nine ASX healthcare leaders, the global pathology and diagnostics group behind them, and the AI thread that connects the two, recorded on Tuesday 10 November 2026.

Which ASX Healthcare Stocks Are Leading the Market Right Now?

Nine ASX-listed healthcare companies were recurring names in FMP's Top 10 momentum data over the week to 9 November 2026: Avita Medical (ASX: AVH), CSL (ASX: CSL), Australian Clinical Labs (ASX: ACL), Healius (ASX: HLS), Cochlear (ASX: COH), Pro Medicus (ASX: PME), Paragon Care (ASX: PGC), Singular Health (ASX: SHG) and Neuren Pharmaceuticals (Neuren (ASX: NEU)).

Their quarterly gains ran from 5.73% (Neuren) to 114.72% (Avita Medical, covered in the AVITA Medical research note), with CSL at 42.86% and Australian Clinical Labs at 33.66% in between. Monthly gains ran from 3.39% (Paragon Care) to 27.32% (Healius). The monthly figure matters to the analysis. A quarterly gain describes what has already happened, and Christopher Hall's observation is that the group only stays relevant to a momentum trader if that pace of performance continues into the following month.

The healthcare label alone does not narrow the field much. It spans medical devices, pharmaceuticals, pathology, hearing implants and imaging software. FMP's record of the public weekly ASX Top 10 momentum list shows how persistent the theme has been: across the 24 weeks FMP has published that research, medical devices appeared in the Top 10 in 14 of the weeks, and healthcare companies appeared in 17 of them.

Why Does Sector and Thematic Leadership Matter More Than a Single Stock?

Market-leading themes tend to move in packs, so the group a stock belongs to carries more information than the stock alone. Two pieces of independent research support the point, both on US data. Moskowitz and Grinblatt (1999), in the Journal of Finance, studied US equities from 1963 to 1995 and found that 60–73% of momentum profits derive from sector and industry effects rather than individual stock selection. Thomas Bulkowski, an independent market researcher and author of Encyclopedia of Chart Patterns (Wiley), studied 512 stocks across 44 industries between 1995 and 2007 and reported that stocks in the top-ranked industry by relative strength returned 98% over two years, against 12% for stocks in the bottom-ranked industry. Both are historical findings from US markets, and the relationship may differ on the ASX.

Think of a single stock in a leading group as one wave inside a rising tide. The tide is the information. That is why FMP groups companies by thematic rather than by a fixed classification, a distinction set out in the thematic solution to GICS. A sector label places a company by what it sells. A thematic places it by what is driving capital toward it, and the two do not always agree.

What Does the Global Pathology and Diagnostics Group Show?

The ASX nine were the starting screen, and widening it to global markets showed which part of healthcare capital was favouring. Christopher Hall's method is to take the quarterly momentum leaders on each exchange, study every one for several weeks, and look for the ones that move together. Industries or sectors usually explain the grouping, and there is normally an outlier that sits outside it. In this case the outlier is what connected the dots.

Across the leaders FMP tracks, most of the healthcare names that kept appearing were pathology and diagnostics companies, businesses that collect clinical data in their niche. One company was different.

Ticker

Company (index)

What it does

FMP momentum record

ACL

Australian Clinical Labs (ASX)

Pathology, including molecular and genetic tests

5 of 5 sessions, #15

MYGN

Myriad Genetics (Russell)

Hereditary-risk and cancer genetic tests

6 of 7 sessions, #2

PACB

PacBio (Russell)

Long-read DNA sequencing instruments

4 of 7 sessions, #4

NAUT

Nautilus (Russell)

Protein-analysis tools

4 of 7 sessions, #1

CDNA

CareDx (Russell)

Transplant diagnostics

4 of 7 sessions, #7

GRAL

GRAIL (Russell)

Multi-cancer blood test

3 of 7 sessions, #11

HTFL

HeartFlow (Russell)

AI analysis of cardiac scans

2 of 7 sessions, #28

Source: FMP momentum data. The record column shows the number of sessions each company appeared in, out of the sessions counted, with its rank.

Australian Clinical Labs describes itself as Australia's third-largest private pathology provider, with more than 1,000 collection centres. Myriad Genetics focuses on oncology, women's health and mental health testing. GRAIL's Galleri test is described by the company as the first multi-cancer early detection blood test available in the US. HeartFlow is the outlier: it uses software and AI to build a personalised 3D model of a patient's heart from a single coronary CT angiography scan. Where the others gather clinical data, HeartFlow applies AI to turn data collected in healthcare into faster insight.

A looser group of healthcare leaders sat alongside these on the same lists without sharing the data-collection role: DexCom (continuous glucose sensors), Intuitive Surgical (surgical robots, 10 of 10 sessions, #4), Glaukos (eye devices), Certara (drug-development software), Cochlear (hearing implants), CVS Group (veterinary clinics) and Apollo Hospitals (hospitals with a diagnostics arm, seven Launch Pad sessions, best rank #1).

The share-price performance is consistent with capital flowing toward the group. It does not establish why, and Christopher Hall's reading is that the investment driver is the role AI plays in turning clinical data into insight, with HeartFlow as the visible example.

The FMP Momentum Profile — published daily and accessible to FMP YouTube Momentum Profile members — tracks the market conditions that form the context for thematic articles like this one. Members receive early access to the educational data discussed in each weekly session.

Why Is Data, Not Computing Power, the Bottleneck for AI in Healthcare?

Computing power is more available now than it was a year ago, so the limiting input for medical AI is increasingly data: cleaner, sharper and deeper. That is Christopher Hall's observation, and it matches what AI researcher Richard Socher says about biology. Richard Socher is the former chief scientist at Salesforce, the founder of the search company you.com and now CEO of Recursive, a company building AI systems for scientific research. On the TWiML AI Podcast he put it this way:

"I think we can get much further still if we just collect more data on biology."

He added that the problem looks impossible at first, then:

"But it is to a large degree a data problem."

His explanation for why language and software moved first is a useful guide to what biology still lacks. He says AI reaches superhuman performance in a field when there is effectively unlimited data, a simulation that can be run endlessly, or a verifier that can check answers. Language models had the first, because, in his words, "humanity has kind of collected together tons of data on language on the internet." Chess and many other games had the second and third. Biology has none of the three:

"biology is not in any of those three right now"

and, he says, "we need to collect a ton more data" to build simulations that researchers can experiment inside. Software iterates quickly, whereas "molecules and atoms are harder to move around," so biology moves more slowly than pure software, and regulatory approvals add further time.

Richard Socher did not discuss pathology companies or any of the ASX stocks in this article. The link between his point and the list above is Christopher Hall's inference: pathology and diagnostics businesses are among the organisations that generate the volume of clinical data that medical AI needs. Christopher Hall also observes that researchers across fields from mathematics to biotechnology report struggling to keep pace with the volume of new papers, which generative AI is both accelerating and helping them manage. That is an observation, not a documented study.

The host of the Milk Road Stocks interview framed the wider shift as a move from the first phase of the AI boom, investing in the companies building intelligence, toward the discoveries that intelligence produces. The ASX healthcare group is one place where that second phase could be visible in the data, though that is a possibility rather than a conclusion.

What Is AI Already Doing in Biotech, According to Richard Socher?

Richard Socher points to several biotech companies where AI is already part of the process, and he is open that his views come from an interested position. He runs AIX Ventures, a venture fund, and said on the TWiML AI Podcast that it invested in the seed round of Profluent and in Parallel Bio, both of which he cites below. He is also CEO of Recursive. His comments are those of a participant in the field, not an independent observer.

  • Parallel Bio: he says the company uses human stem cells to grow organoids, tiny working models of organs, and AI to track every cell as drugs interact with them. In the Milk Road Stocks interview he said the company received full FDA approval to skip animal trials, because human organoids can be more predictive of how a drug interacts with the immune system than a mouse. These are his statements and have not been independently verified by FMP.

  • Profluent: he says the company designs proteins for DNA manipulation and has closed a contract worth more than two billion dollars with Eli Lilly to bring that work into clinical practice.

  • Virtual cells: he describes a virtual cell as a digital twin, a full simulation of a cell. It is still some way off, and as he said of the data it depends on, "you need to have that kind of data collection to get there."

He is equally direct about timing. Biotech progress is slower than software, in his words "in biology everything is slower," and approvals, while speeding up, are still quite slow. That caution is relevant to how any healthcare AI theme is read. For how a regulatory milestone changes a biotech's economics, see how ASX biotech FDA approval changes a share price.

What Are the Risks of Treating an AI Healthcare Theme as Market Leadership?

Quarterly momentum records what has already risen, and it says nothing about what will rise next. The same ASX data that shows nine leaders by quarter shows a weaker picture over twelve months. As at 9 November 2026, five of the nine were lower over the year: Paragon Care (−77.32%), Cochlear (−61.37%), Healius (−52.92%), Singular Health (−25.13%) and Pro Medicus (−21.13%). Four were higher: Avita Medical (+152.07%), Australian Clinical Labs (+27.88%), Neuren (+25.85%) and CSL (+13.42%). Several of the nine are rebounding within a longer decline, which is a different situation from a sustained leadership run.

Other risks sit outside the price data:

  • Interpretation risk. The pathology-to-data-to-AI chain is a reasoned link, not a measured one. No dataset here demonstrates that AI demand is what is driving these share prices.

  • Timing risk. Richard Socher himself says biology is slower than software, and wet-lab work and regulatory approval take time.

  • Source risk. His examples come from a venture investor and company founder with direct interests in several of the companies he names.

  • Theme risk. Christopher Hall's view is that healthcare and AI may be the next driving theme if the broader market turns, but that depends on the theme becoming dominant, and that has not yet happened.

For traders who prefer diversified exposure to the sector rather than single names, a comparison of ASX-listed healthcare funds is in Best Healthcare ETFs ASX.

Conclusion

ASX healthcare momentum, a global group of pathology and diagnostics leaders, and one AI company that connects them point to the same idea: medical AI depends on data, and the companies that collect clinical data are where the share-price performance has shown up. Richard Socher's comments on data, simulation and the slower pace of biology give that idea independent context, while the twelve-month figures show how selective the leadership is. The development to watch is the news flow from the AI-in-healthcare company that linked the group and whether the healthcare theme keeps appearing in the weekly Top 10, which is an observation, not a signal to trade. The FMP Momentum Profile and the Finer Market Points weekly session recordings — where market conditions like those discussed in this article are reviewed in real time — are accessible to FMP YouTube Momentum Profile members.

This article draws on publicly available research data compiled for the Finer Market Points editorial program. The FMP Momentum Profile and the Finer Market Points weekly session recordings — where ASX momentum stocks and the market conditions covered in thematic articles like this one are reviewed in real time — are accessible to FMP YouTube Momentum Profile members. Members receive early access to the educational data that forms the basis of articles like this one. For information on FMP YouTube Momentum Profile membership, visit the FMP membership page.

Remember that past performance is no guarantee of future results, and all trading involves risk.

Frequently Asked Questions

What are the best performing ASX healthcare stocks right now?

As at 9 November 2026, FMP's momentum data showed nine ASX healthcare companies leading on quarterly performance: Avita Medical (AVH) 114.72%, CSL (CSL) 42.86%, Australian Clinical Labs (ACL) 33.66%, Healius (HLS) 19.90%, Cochlear (COH) 19.70%, Pro Medicus (PME) 14.81%, Paragon Care (PGC) 14.31%, Singular Health (SHG) 10.01% and Neuren (NEU) 5.73%. Momentum ranks recent price performance. It is not a recommendation or a forecast.

Why does AI in healthcare depend on data from pathology and diagnostics companies?

Christopher Hall's observation is that the limit on AI in medicine is no longer computing power but the volume and depth of clean data, and pathology and diagnostics businesses collect clinical samples and results at scale. Richard Socher, CEO of Recursive, says biology "is to a large degree a data problem." The link between the two is Christopher Hall's inference, not a finding by Richard Socher.

What is a virtual cell and why does it matter for biotech?

In the TWiML AI Podcast interview, Richard Socher described a virtual cell as a digital twin of an actual cell, a full simulation that would let researchers run experiments in software instead of a wet lab. He said it is still some way off and that "you need to have that kind of data collection to get there." Organoid testing is one source of that data he cites.

Why has AI progressed faster in software and language than in biology?

Richard Socher says language models learned from the enormous volume of text people have put on the internet, and software can be tested and changed quickly. Biology is slower because "molecules and atoms are harder to move around," and wet-lab work and regulatory approvals add time. He adds that biology currently lacks unlimited data, a reliable simulation and a fast way to verify answers.

What did Richard Socher say about organoids and animal testing?

In the Milk Road Stocks interview, Richard Socher said Parallel Bio, a company AIX Ventures invested in, received FDA approval to skip animal trials by using human organoids, which he said can be more predictive of how a drug interacts with the immune system than a mouse. AI is used to track the organoids. These are his statements, and FMP has not independently verified the regulatory claim.

Is a quarterly momentum ranking a recommendation to buy a healthcare stock?

No. FMP's momentum data records which companies have risen most over a period. It describes what has already happened and is general educational information, not advice or a forecast. Five of the nine ASX healthcare names in this article are lower over twelve months, which shows why a strong quarter and a strong year are different measures.

What is the difference between a healthcare sector and a healthcare thematic?

A sector such as GICS healthcare is a fixed classification that groups companies by what they sell. A thematic groups companies by the investment driver moving their share prices, so it can cut across sectors, for example pathology, genetic testing and diagnostic software. FMP uses thematics because the common thread between a group of leaders often sits outside the sector label.

About the Author

Christopher Hall, AdvDipFP, is an Authorised Representative (AFSL 526688) and the editorial lead at Finer Market Points, covering ASX-listed momentum stocks and market data for an Australian trading audience. Read more on the author's profile page.

Sources

#

Source

Type

1

Christopher Hall, Finer Market Points recorded session, "Why AI Is Quietly Taking Over Healthcare's Top ASX Movers", 10 November 2026: youtube.com/live/STM5FvSacdg

FMP proprietary data

2

FMP ASX momentum data (weekly, monthly, quarterly and twelve-month returns), as at 9 November 2026

FMP proprietary data

3

FMP weekly Top 10 ASX momentum list, 24-week thematic record (medical devices 14 weeks, healthcare 17 weeks)

FMP proprietary data

4

FMP global momentum data: pathology, diagnostics and healthcare leaders (ASX, Russell, Nasdaq 100, FTSE 250, Nifty 50)

FMP proprietary data

5

Sam Charrington with Richard Socher, TWiML AI Podcast, "What Happens When AI Starts Improving Itself?": youtube.com/watch?v=rIUcQfyXuUo

Expert interview (published)

6

LG Ducet with Richard Socher, Milk Road Stocks, "Richard Socher: The Biggest AI Breakthroughs Haven't Happened Yet", 21 September 2026: youtube.com/watch?v=6kBqX0vFDk0

Expert interview (published)

7

Moskowitz, T.J. and Grinblatt, M. (1999), "Do Industries Explain Momentum?", Journal of Finance, 54(4), 1249–1290

Published research

8

Bulkowski, T., industry relative strength study (512 stocks, 44 industries, 1995–2007), thepatternsite.com

Published research

9

Company descriptions for Australian Clinical Labs, Myriad Genetics, PacBio, Nautilus, CareDx, GRAIL and HeartFlow as published by each company

Company disclosure

Richard Socher's statements are quoted from published interviews, with spoken-word fillers removed. He did not discuss the ASX companies named in this article. The pathology and diagnostics data-collector link is Christopher Hall's inference.

Related Finer Market Points Educational Resources

This content is for educational purposes only and does not constitute financial advice. Past performance is no guarantee of future results.

The information, opinions and other materials appearing on this website are of a general nature only and shall not be construed as advice. Finer Market Points Pty Ltd, CAR 1304002, AFSL 526688, ABN 87 645 284 680. This general information is educational only and not financial advice, recommendation, forecast or solicitation. This is not taxation advice. Rose Bay Equities accepts no responsibility for the accuracy or completeness of the information, opinions or other materials provided on or accessible through this website. This website has not been prepared with reference to your individual financial or personal circumstances. You should not rely on any advice on this website without first seeking appropriate professional, financial and legal advice. Further, where Rose Bay Equities makes third party material available or accessible through this website you acknowledge that Rose Bay Equities is a distributor and not a publisher of that content and that its editorial control is limited to the selection of those materials to make available. We accept no liability for any loss or damages arising from use. Authors and presenters may hold positions in discussed companies and investment products.

Recent Posts

See All

Comments


bottom of page